1
|
Marastoni D, Colato E, Foschi M, Tamanti A, Ziccardi S, Eccher C, Crescenzo F, Bajrami A, Schiavi GM, Camera V, Anni D, Virla F, Guandalini M, Turano E, Pizzini FB, Montemezzi S, Bonetti B, Howell O, Magliozzi R, Nicholas RS, Scalfari A, Granziera C, Kappos L, Calabrese M. Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis. NEUROLOGY(R) NEUROIMMUNOLOGY & NEUROINFLAMMATION 2025; 12:e200399. [PMID: 40311103 PMCID: PMC12056761 DOI: 10.1212/nxi.0000000000200399] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2025] [Accepted: 03/10/2025] [Indexed: 05/03/2025]
Abstract
BACKGROUND AND OBJECTIVES The objective of this study was to determine, at the time of diagnosis, a CSF and MRI profile of intrathecal compartmentalized inflammation predictive of progression independent of relapse activity (PIRA) in early relapsing-remitting multiple sclerosis (RRMS). METHODS This five-year prospective study included 80 treatment-naïve patients with RRMS enrolled at time of diagnosis. All patients underwent a lumbar puncture, regular neurologic evaluations including an Expanded Disability Status Scale (EDSS) assessment every 6 months, and an annual 3T brain MRI. PIRA was defined as having a confirmed disability progression independent of relapse activity. CSF levels of 68 inflammatory molecules were evaluated in combination with white matter and cortical lesion number (CLn) and volume, and regional gray matter thickness and volume. RESULTS During the follow-up, 23 patients with RRMS (28.8%) experienced PIRA. At diagnosis, participants with PIRA were older (44.0 ± 10.7 vs 37.4 ± 12.4, p = 0.017) and with more disability (median EDSS score [interquartile range] of 3 [range 2-4] for PIRA vs 1.5 [range 1-2] for no PIRA group, p < 0.001). Random forest selected LIGHT, CXCL13, sTNFR1, sTNFR2, CCL7, MIF, sIL6Rbeta, IL35, CCL2, and IFNβ as the CSF markers best associated with PIRA. sTNFR1 (hazard ratio [HR] 10.11 [2.61-39.10], p = 0.001), sTNFR2 (HR 5.05 [1.63-15.64], p = 0.005), and LIGHT (HR 1.79 [1.11-2.88], p = 0.018) were predictors of PIRA at regression analysis. Baseline thalamus volume (HR 0.98 [0.97-0.99], p = 0.005), middle frontal gyrus thickness (HR 0.05 [0.01-0.72], p = 0.028), and CLn (HR 1.15 [1.05-1.25], p = 0.003) were MRI predictors of PIRA. DISCUSSION A specific intrathecal inflammatory profile associated with TNF superfamily markers, CLn, and atrophy of several cortical and deep gray matter regions, assessed at time of diagnosis, is predictive of PIRA in early MS.
Collapse
Affiliation(s)
- Damiano Marastoni
- Neurology B, Department of Neurosciences, University of Verona, Italy
| | - Elisa Colato
- Neurology B, Department of Neurosciences, University of Verona, Italy
- MS Centre, Department of Anatomy and Neuroscience, Amsterdam UMC, location VUmc, the Netherlands
- NMR Research Unit, Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, United Kingdom
| | - Matteo Foschi
- Department of Neuroscience, Multiple Sclerosis Center, Neurology Unit, S.Maria delle Croci Hospital, AUSL Romagna, Ravenna, Italy
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy
| | - Agnese Tamanti
- Neurology B, Department of Neurosciences, University of Verona, Italy
| | - Stefano Ziccardi
- Neurology B, Department of Neurosciences, University of Verona, Italy
| | - Chiara Eccher
- Neurology B, Department of Neurosciences, University of Verona, Italy
| | | | - Albulena Bajrami
- Neurology B, Department of Neurosciences, University of Verona, Italy
| | | | - Valentina Camera
- Neurology B, Department of Neurosciences, University of Verona, Italy
| | - Daniela Anni
- Neurology B, Department of Neurosciences, University of Verona, Italy
| | - Federica Virla
- Neurology B, Department of Neurosciences, University of Verona, Italy
| | | | - Ermanna Turano
- Neurology B, Department of Neurosciences, University of Verona, Italy
| | | | - Stefania Montemezzi
- Radiology Unit, Department of Pathology and Diagnostics, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
| | - Bruno Bonetti
- Neurology A, Azienda Ospedaliera Universitaria Integrata di Verona, Italy
| | - Owain Howell
- Institute of Life Sciences, Swansea University, United Kingdom
| | - Roberta Magliozzi
- Neurology B, Department of Neurosciences, University of Verona, Italy
- Centre for Neuroscience, Department of Medicine, Charing Cross Hospital, Imperial College London, United Kingdom; and
| | - Richard S Nicholas
- Centre for Neuroscience, Department of Medicine, Charing Cross Hospital, Imperial College London, United Kingdom; and
| | - Antonio Scalfari
- Centre for Neuroscience, Department of Medicine, Charing Cross Hospital, Imperial College London, United Kingdom; and
| | - Cristina Granziera
- Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel, Switzerland
| | - Ludwig Kappos
- Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital and University of Basel, Switzerland
| | | |
Collapse
|
2
|
Stadelmann C, Franz J, Nessler S. Recent developments in multiple sclerosis neuropathology. Curr Opin Neurol 2025; 38:173-179. [PMID: 40178490 PMCID: PMC12052066 DOI: 10.1097/wco.0000000000001370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2025]
Abstract
PURPOSE OF REVIEW Neuropathological studies in human brain tissue are indispensable for our understanding of disease mechanisms in multiple sclerosis (MS). They inform concepts of lesion evolution, tissue regeneration and disease progression, and ideally reveal new disease mechanisms and therapeutic targets. Here we review recent neuropathological studies that have advanced our knowledge of MS pathogenesis. RECENT FINDINGS Recent cohort studies support the notion that different clinical MS disease phenotypes share underlying pathological features, and that clinical and pathological heterogeneity is derived from a variable combination of innate and adaptive inflammation, demyelinating activity, and neuroaxonal loss. Importantly, emerging technologies for spatial transcriptome analysis enable an unprecedented glimpse into the cellular composition and molecular mechanisms involved in lesion evolution. These promising technologies will help identify the identification of molecular hubs governing tissue damage and regeneration. SUMMARY Recent neuropathological studies helped to identify tissue correlates of disability and disease progression. Substantial progress in molecular brain tissue analysis revealed the complexity of MS-related tissue features. Close collaboration between tissue-based, molecular, bioinformatic, pharmacologic, imaging and clinical experts is needed to continue to advance the field, particularly for the benefit of people with progressive MS.
Collapse
Affiliation(s)
- Christine Stadelmann
- Department of Neuropathology, University Medical Center Göttingen, Göttingen, Germany
| | | | | |
Collapse
|
3
|
Filippi M, Preziosa P, Barkhof F, Ciccarelli O, Cossarizza A, De Stefano N, Gasperini C, Geraldes R, Granziera C, Haider L, Lassmann H, Margoni M, Pontillo G, Ropele S, Rovira À, Sastre-Garriga J, Yousry TA, Rocca MA. The ageing central nervous system in multiple sclerosis: the imaging perspective. Brain 2024; 147:3665-3680. [PMID: 39045667 PMCID: PMC11531849 DOI: 10.1093/brain/awae251] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Revised: 06/10/2024] [Accepted: 06/23/2024] [Indexed: 07/25/2024] Open
Abstract
The interaction between ageing and multiple sclerosis is complex and carries significant implications for patient care. Managing multiple sclerosis effectively requires an understanding of how ageing and multiple sclerosis impact brain structure and function. Ageing inherently induces brain changes, including reduced plasticity, diminished grey matter volume, and ischaemic lesion accumulation. When combined with multiple sclerosis pathology, these age-related alterations may worsen clinical disability. Ageing may also influence the response of multiple sclerosis patients to therapies and/or their side effects, highlighting the importance of adjusted treatment considerations. MRI is highly sensitive to age- and multiple sclerosis-related processes. Accordingly, MRI can provide insights into the relationship between ageing and multiple sclerosis, enabling a better understanding of their pathophysiological interplay and informing treatment selection. This review summarizes current knowledge on the immunopathological and MRI aspects of ageing in the CNS in the context of multiple sclerosis. Starting from immunosenescence, ageing-related pathological mechanisms and specific features like enlarged Virchow-Robin spaces, this review then explores clinical aspects, including late-onset multiple sclerosis, the influence of age on diagnostic criteria, and comorbidity effects on imaging features. The role of MRI in understanding neurodegeneration, iron dynamics and myelin changes influenced by ageing and how MRI can contribute to defining treatment effects in ageing multiple sclerosis patients, are also discussed.
Collapse
Affiliation(s)
- Massimo Filippi
- Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Neurology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Neurophysiology Service, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Vita-Salute San Raffaele University, 20132 Milan, Italy
| | - Paolo Preziosa
- Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Neurology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Vita-Salute San Raffaele University, 20132 Milan, Italy
| | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands
- Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London WC1N 3BG, UK
| | - Olga Ciccarelli
- Queen Square MS Centre, UCL Institute of Neurology, UCL, London WC1N 3BG, UK
- NIHR (National Institute for Health and Care Research) UCLH (University College London Hospitals) BRC (Biomedical Research Centre), London WC1N 3BG, UK
| | - Andrea Cossarizza
- Department of Medical and Surgical Sciences for Children and Adults, University of Modena and Reggio Emilia, 42121 Modena, Italy
| | - Nicola De Stefano
- Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy
| | - Claudio Gasperini
- Department of Neurosciences, S Camillo Forlanini Hospital Rome, 00152 Rome, Italy
| | - Ruth Geraldes
- Clinical Neurology, John Radcliffe Hospital, Oxford University Foundation Trust, Oxford OX3 9DU, UK
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK
| | - Cristina Granziera
- Department of Neurology, University Hospital Basel and University of Basel, 4031 Basel, Switzerland
- Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel and University of Basel, 4031 Basel, Switzerland
- Translational Imaging in Neurology (ThINk) Basel, Department of Biomedical Engineering, University Hospital Basel and University of Basel, 4031 Basel, Switzerland
| | - Lukas Haider
- Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London WC1N 3BG, UK
- Department of Biomedical Imaging and Image Guided Therapy, Medical University of Vienna, 1090 Vienna, Austria
| | - Hans Lassmann
- Center for Brain Research, Medical University of Vienna, 1090 Vienna, Austria
| | - Monica Margoni
- Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Neurology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Neurorehabilitation Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
| | - Giuseppe Pontillo
- Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit, 1081 HV Amsterdam, The Netherlands
- Queen Square Institute of Neurology and Centre for Medical Image Computing, University College London, London WC1N 3BG, UK
- Department of Advanced Biomedical Sciences, University “Federico II”, 80138 Naples, Italy
| | - Stefan Ropele
- Department of Neurology, Medical University of Graz, 8010 Graz, Austria
| | - Àlex Rovira
- Neuroradiology Section, Department of Radiology, Hospital Universitari Vall d'Hebron, 08035 Barcelona, Spain
| | - Jaume Sastre-Garriga
- Neurology Department and Multiple Sclerosis Centre of Catalunya (Cemcat), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain
| | - Tarek A Yousry
- Lysholm Department of Neuroradiology, UCLH National Hospital for Neurology and Neurosurgery, Neuroradiological Academic Unit, UCL Institute of Neurology, London WC1N 3BG, UK
| | - Maria A Rocca
- Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Neurology Unit, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy
- Vita-Salute San Raffaele University, 20132 Milan, Italy
| |
Collapse
|
4
|
Tunç A, Danisan G, Taydas O, Kara AB, Öncel S, Özdemir M. Differential Analysis of Venous Sinus Diameters: Unveiling Vascular Alterations in Patients with Multiple Sclerosis. Diagnostics (Basel) 2024; 14:1760. [PMID: 39202247 PMCID: PMC11353770 DOI: 10.3390/diagnostics14161760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2024] [Revised: 07/26/2024] [Accepted: 07/30/2024] [Indexed: 09/03/2024] Open
Abstract
BACKGROUND Alterations in the cerebral venous system have been increasingly recognized as a significant component of the pathophysiology of multiple sclerosis (MS). This study aimed to explore the relationship between venous sinus diameter and MS to understand potential vascular alterations in MS patients compared with controls. We sought to determine whether these alterations were correlated with disease characteristics such as duration, lesion type, and disability score. METHODS This study included 79 MS patients diagnosed according to the 2017 McDonald criteria and 67 healthy individuals. Magnetic resonance imaging (MRI) scans via a 1.5 Tesla system provided measurements of the superior sagittal sinus, right and left transverse sinus, sinus rectus, and venous structures. Statistical analysis was conducted via SPSS, employing independent sample t tests, ANOVA, chi-square tests, and Pearson correlation analysis, with the significance level set at p < 0.05. RESULTS This study revealed significant differences in venous sinus diameter between MS patients and controls, with MS patients exhibiting larger diameters. Specifically, patients with brainstem and spinal lesions had larger diameters in certain sinus regions. No significant correlations were found between venous sinus diameter and demographic factors, expanded disability status scale scores, or lesion counts. However, a significant increase in perivenular lesions was noted in patients with longer disease durations. CONCLUSIONS The findings indicate notable vascular alterations in MS patients, particularly in venous sinus diameters, suggesting a potential vascular component in MS pathology. The lack of correlation with conventional clinical and MRI metrics highlights the complexity of MS pathology. These insights underscore the need for further research, particularly longitudinal studies, to elucidate the role of venous changes in MS progression and their potential as therapeutic targets.
Collapse
Affiliation(s)
- Abdulkadir Tunç
- Department of Neurology, Faculty of Medicine, Sakarya University, 54100 Sakarya, Turkey
| | - Gurkan Danisan
- Department of Radiology, Faculty of Medicine, Sakarya University, 54100 Sakarya, Turkey; (G.D.); (O.T.); (M.Ö.)
| | - Onur Taydas
- Department of Radiology, Faculty of Medicine, Sakarya University, 54100 Sakarya, Turkey; (G.D.); (O.T.); (M.Ö.)
| | - Ahmet Burak Kara
- Department of Radiology, Faculty of Medicine, Sakarya University, 54100 Sakarya, Turkey; (G.D.); (O.T.); (M.Ö.)
| | - Samet Öncel
- Department of Neurology, Sakarya University Training and Research Hospital, 54100 Sakarya, Turkey;
| | - Mustafa Özdemir
- Department of Radiology, Faculty of Medicine, Sakarya University, 54100 Sakarya, Turkey; (G.D.); (O.T.); (M.Ö.)
| |
Collapse
|
5
|
Mistry N, Hobart J, Rog D, Muhlert N, Mathews J, Baker D, Giovannoni G. Reconciling lesions, relapses and smouldering associated worsening: A unifying model for multiple sclerosis pathogenesis. Mult Scler Relat Disord 2024; 88:105706. [PMID: 38880031 DOI: 10.1016/j.msard.2024.105706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2024] [Revised: 05/31/2024] [Accepted: 06/07/2024] [Indexed: 06/18/2024]
Abstract
The failure of relapses and white matter lesions to properly explain long-term disability and progression in multiple sclerosis is compounded by its artificial separation into relapsing remitting, secondary progressive, and primary progressive pigeonholes. The well-known epidemiological disconnection between relapses and long-term disability progression has been rediscovered as "progression independent of relapse activity", i.e. smouldering multiple sclerosis. This smouldering associated worsening proceeds despite early and prolonged use of disease modification therapies, even those that are highly effective at preventing relapses and new/enhancing white matter lesions on MRI. We recognise that smouldering associated worsening and relapse/lesion associated worsening coexist, to varying extents. The extent of cortical demyelination has been shown to correlate significantly with the severity of diffuse injury in normal appearing white matter (post mortem histopathologically (r = 0.55; P = 0.001), and in vivo with MRI (r = -0.6874; P = 0.0006)) and does so independently of white matter lesion burden. Axon loss in the normal appearing white matter explains disability in multiple sclerosis better than focal white matter lesions do. Smouldering associated worsening typically manifests as a length-dependent central axonopathy. We propose a unifying model for multiple sclerosis pathogenesis, wherein accumulation of cortical lesion burden predisposes associated normal appearing white matter to diffuse injury, whilst also intensifying damage within white matter lesions. Our novel two-hit hypothesis implicates cortical disease as a culprit for smouldering multiple sclerosis, abetted by active focal inflammation in the white matter (and vice versa). Substantiation of the two-hit hypothesis would advance the importance of specific therapeutic intervention for (and monitoring of) cortical/meningeal inflammation in people with multiple sclerosis.
Collapse
Affiliation(s)
- Niraj Mistry
- Department of Clinical Neurosciences, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
| | - Jeremy Hobart
- Peninsula Schools of Medicine and Dentistry, University of Plymouth, Plymouth, UK
| | - David Rog
- Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK
| | - Nils Muhlert
- School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| | - Joela Mathews
- Department of Neurology, The Royal London Hospital, London, UK
| | - David Baker
- Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Gavin Giovannoni
- Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK
| |
Collapse
|
6
|
Cooze B, Neal J, Vineed A, Oliveira JC, Griffiths L, Allen KH, Hawkins K, Yadanar H, Gerhards K, Farkas I, Reynolds R, Howell O. Digital Pathology Identifies Associations between Tissue Inflammatory Biomarkers and Multiple Sclerosis Outcomes. Cells 2024; 13:1020. [PMID: 38920650 PMCID: PMC11201856 DOI: 10.3390/cells13121020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2024] [Revised: 05/22/2024] [Accepted: 05/29/2024] [Indexed: 06/27/2024] Open
Abstract
BACKGROUND Multiple sclerosis (MS) is a clinically heterogeneous disease underpinned by inflammatory, demyelinating and neurodegenerative processes, the extent of which varies between individuals and over the course of the disease. Recognising the clinicopathological features that most strongly associate with disease outcomes will inform future efforts at patient phenotyping. AIMS We used a digital pathology workflow, involving high-resolution image acquisition of immunostained slides and opensource software for quantification, to investigate the relationship between clinical and neuropathological features in an autopsy cohort of progressive MS. METHODS Sequential sections of frontal, cingulate and occipital cortex, thalamus, brain stem (pons) and cerebellum including dentate nucleus (n = 35 progressive MS, females = 28, males = 7; age died = 53.5 years; range 38-98 years) were immunostained for myelin (anti-MOG), neurons (anti-HuC/D) and microglia/macrophages (anti-HLA). The extent of demyelination, neurodegeneration, the presence of active and/or chronic active lesions and quantification of brain and leptomeningeal inflammation was captured by digital pathology. RESULTS Digital analysis of tissue sections revealed the variable extent of pathology that characterises progressive MS. Microglia/macrophage activation, if found at a higher level in a single block, was typically elevated across all sampled blocks. Compartmentalised (perivascular/leptomeningeal) inflammation was associated with age-related measures of disease severity and an earlier death. CONCLUSION Digital pathology identified prognostically important clinicopathological correlations in MS. This methodology can be used to prioritise the principal pathological processes that need to be captured by future MS biomarkers.
Collapse
Affiliation(s)
- Benjamin Cooze
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| | - James Neal
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| | - Alka Vineed
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| | - J. C. Oliveira
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| | - Lauren Griffiths
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| | - K. H. Allen
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| | - Kristen Hawkins
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| | - Htoo Yadanar
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| | - Krisjanis Gerhards
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| | - Ildiko Farkas
- Division of Brain Sciences, Imperial College London, London SW7 2AZ, UK; (I.F.); (R.R.)
| | - Richard Reynolds
- Division of Brain Sciences, Imperial College London, London SW7 2AZ, UK; (I.F.); (R.R.)
| | - Owain Howell
- Faculty of Medicine, Health & Life and Health Sciences, Swansea University, Swansea SA2 8PP, UK; (B.C.); (A.V.); (J.C.O.); (L.G.); (K.H.A.); (K.H.); (H.Y.); (K.G.); (O.H.)
| |
Collapse
|
7
|
Waldman AD, Catania C, Pisa M, Jenkinson M, Lenardo MJ, DeLuca GC. The prevalence and topography of spinal cord demyelination in multiple sclerosis: a retrospective study. Acta Neuropathol 2024; 147:51. [PMID: 38460050 PMCID: PMC10924711 DOI: 10.1007/s00401-024-02700-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 01/12/2024] [Accepted: 01/27/2024] [Indexed: 03/11/2024]
Abstract
Spinal cord pathology is a major determinant of irreversible disability in progressive multiple sclerosis. The demyelinated lesion is a cardinal feature. The well-characterised anatomy of the spinal cord and new analytic approaches allows the systematic study of lesion topography and its extent of inflammatory activity unveiling new insights into disease pathogenesis. We studied cervical, thoracic, and lumbar spinal cord tissue from 119 pathologically confirmed multiple sclerosis cases. Immunohistochemistry was used to detect demyelination (PLP) and classify lesional inflammatory activity (CD68). Prevalence and distribution of demyelination, staged by lesion activity, was determined and topographical maps were created to identify patterns of lesion prevalence and distribution using mixed models and permutation-based voxelwise analysis. 460 lesions were observed throughout the spinal cord with 76.5% of cases demonstrating at least 1 lesion. The cervical level was preferentially affected by lesions. 58.3% of lesions were inflammatory with 87.9% of cases harbouring at least 1 inflammatory lesion. Topographically, lesions consistently affected the dorsal and lateral columns with relative sparing of subpial areas in a distribution mirroring the vascular network. The presence of spinal cord lesions and the proportion of active lesions related strongly with clinical disease milestones, including time from onset to wheelchair and onset to death. We demonstrate that spinal cord demyelination is common, highly inflammatory, has a predilection for the cervical level, and relates to clinical disability. The topography of lesions in the dorsal and lateral columns and relative sparing of subpial areas points to a role of the vasculature in lesion pathogenesis, suggesting short-range cell infiltration from the blood and signaling molecules circulating in the perivascular space incite lesion development. These findings challenge the notion that end-stage progressive multiple sclerosis is 'burnt out' and an outside-in lesional gradient predominates in the spinal cord. Taken together, this study provides support for long-term targeting of inflammatory demyelination in the spinal cord and nominates vascular dysfunction as a potential target for new therapeutic approaches to limit irreversible disability.
Collapse
Affiliation(s)
- Alex D Waldman
- Nuffield Department of Clinical Neurosciences, University of Oxford, Level 1, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU, UK
- Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Cecilia Catania
- Nuffield Department of Clinical Neurosciences, University of Oxford, Level 1, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU, UK
| | - Marco Pisa
- Nuffield Department of Clinical Neurosciences, University of Oxford, Level 1, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU, UK
| | - Mark Jenkinson
- Wellcome Centre for Integrative Neuroimaging, Nuffield Department of Clinical Neurosciences, Oxford Centre for Functional MRI of the Brain, John Radcliffe Hospital, Oxford, OX3 9DU, UK
- Australian Institute for Machine Learning (AIML), School of Computer and Mathematical Sciences, University of Adelaide, Adelaide, Australia
- South Australian Health and Medical Research Institute (SAHMRI), Adelaide, Australia
| | - Michael J Lenardo
- Molecular Development of the Immune System Section, Laboratory of Immune System Biology and Clinical Genomics Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA
| | - Gabriele C DeLuca
- Nuffield Department of Clinical Neurosciences, University of Oxford, Level 1, West Wing, John Radcliffe Hospital, Oxford, OX3 9DU, UK.
| |
Collapse
|